We turn American Heart Association's Science News into an interactive format for you. Find something interesting or have a question? Let us know in the comments.

See the latest Science News from the American Heart Association at professional.heart.org/sciencenews.
 

Latest Posts

With the re-brand and re-launch of our website, Professional Heart Daily, we have made some changes to how we present Science News.

In order to make the experience more about engaging conversations around the statements we publish, we are discontinuing the Science News blog here on the Professional Online Network. As always, the most recently published statements, guidelines and conference coverage will be available on the Professional Heart Daily home page.

We have started including a discussion question with each statement or guideline's coverage. Those discussion questions are published here in the Discussions area. We encourage you to login and tell us and your peers what you think.

Thank you for your support of the Science News blog! We are excited about the changes and look forward to your responses.

Best,
AHA Science News Team
Posted by Stacy AHA Science on Apr 14, 2016 9:17 AM CDT
One Brave Idea


Through a $75 million investment over at least five years, the American Heart Association (AHA), Verily and AstraZeneca are embarking on a groundbreaking research enterprise to prevent and/or reverse coronary heart disease and its consequences.

This is the single largest research project funding one leader and team in the fight to cure coronary heart disease – as well as the most accessible: anyone who believes they have the idea and capabilities to lead a team that can end coronary heart disease and improve cardiovascular health is eligible to apply. The application period is open from Jan. 14–Feb. 14, 2016. Ultimately, the applicant who demonstrates an ability to lead a diverse team of experts, with the most visionary and bold idea, will be the selected leader and awarded the opportunity and challenge to bring this vision to life.

AHA, Verily and AstraZeneca are looking for the one brave idea from a leader with the vision and capability of creating a diverse team of the world’s best and brightest minds. This team will be provided with unprecedented technical, scientific, medical, and financial resources so that they can solve one of the world’s greatest health challenges.

The ultimate goal is to design and implement novel strategies to prevent or reverse the causes and drivers of coronary heart disease, thereby restoring cardiovascular health to patients helping to enhance longevity and improve quality of life around the world.

Traditional research funding models are often incremental and piecemeal and make it difficult to study a long-term, multifaceted subject. Branded as One Brave Idea™, this approach is a fundamentally different kind of model for funding innovation – it is designed to remove the barriers and the silos that plague traditional research projects.

One Brave Idea™ seeks to uncover the drivers of coronary heart disease with an inclusive focus on causative factors and consequences and ultimately to end the disease. Visit www.onebraveidea.com to submit your idea by 11:59 p.m. CT on Feb. 14, 2016.

Posted by Stacy AHA Science on Jan 21, 2016 11:47 AM CST

The 2016 Update of Heart Disease and Stroke Statistics includes:

  • Updated mortality trends for heart disease, stroke and other CV conditions
  • New incidence data for coronary heart disease, heart attack and heart failure
  • Updated incidence and survival rates for cardiac arrest
  • New information on stroke in young adults
  • New emphasis on underserved and minority populations

Read the full article in Circulation


Supporting Materials
Posted by Kelly Kozakowski on Dec 16, 2015 6:07 PM CST
20151105_Banner.jpg

Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape
A Conference Report From the American Heart Association Data Summit 2015

JAHA
  • The AHA Data Summit was a 1.5-day interactive forum convened to discuss critical issues in the acquisition, analysis, and sharing of data in the field of cardiovascular and stroke science.
  • Summit participants represented stakeholders from 7 domains (patients, basic scientists, clinical investigators, population researchers, clinicians and healthcare system administrators, industry, and regulatory authorities) and discussed data as viewed from conventional medical and nonmedical sources, building and using Big Data repositories, articulation of the goals of data sharing, and principles of responsible data sharing.
  • Potential roles that the AHA might consider in the Big Data environment include facilitating a standards discussion, providing education, and helping build an interoperable digital ecosystem in cardiovascular and stroke science.

Read the full article in JAHA


Supporting Materials
 
Related Science
 
 
Circulation
Circulation
DS-9071-SS15-Reg-Banner-585x72.jpg
Posted by Stacy AHA Science on Nov 5, 2015 2:59 PM CST
pediatricPulmoaryHypertension_Banner.jpg

American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension

Hypertension
  • Pulmonary hypertension is associated with diverse cardiac, pulmonary and systemic diseases in neonates, infants and older children and contributes to significant morbidity and mortality.
  • Many gaps remain regarding our knowledge of the developing lung circulation and its response to injury, unique features of PH in children, and optimal clinical evaluations and treatment strategies.
  • These joint guidelines represent consensus from experts in the field addressing current approaches to care.

Read the full article in Circulation


Supporting Materials
 
Resources for your Practice and Patients
 
 
Circulation
Circulation
DS-9071-SS15-Reg-Banner-585x72.jpg
Posted by Kelly Kozakowski on Nov 3, 2015 3:26 PM CST
11022015_Competative_Athlete_Banner.jpg

Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities

Hypertension
The recommendations address organized and sanctioned competitive sports participation.
  • Young trained athletes with underlying cardiovascular abnormalities are at an increased risk for sudden cardiac death.
  • Considerations such as protection of the athlete’s health and avoidance of an unreasonable risks for sudden death during competitive athletics are stressed when addressing medical eligibility versus disqualification decisions, which have become increasingly complex.

Read the full Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities articles in Circulation


Supporting Video
Recommendations for Competitive Athletes with Cardiovascular Abnormalities
   
Supporting Materials
 
Resources for your Practice
For other AHA statements on Athletes and Screening go to:
 
For Your Patients

 
Circulation
Circulation
DS-9071-SS15-Reg-Banner-585x72.jpg
Posted by Kelly Kozakowski on Nov 2, 2015 3:09 PM CST
102815_FamiliaHypercholesterol_banner.jp

The Agenda for Familial Hypercholesterolemia

Hypertension
  • The American Heart Association (AHA) provides an agenda to further familial hypercholesterolemia (FH) diagnosis and treatment practices, building on the platform provided by recent guidelines and reviews of progress in the field.
  • Familial hypercholesterolemia is a highly prevalent, underdiagnosed and undertreated genetic disorder causing premature atherosclerotic coronary artery heart disease.
  • Because FH can be asymptomatic and have potentially devastating consequences.

Read the full article in Circulation


Supporting Materials
 
Related Science
 
 
Circulation
Circulation
DS-9071-SS15-Reg-Banner-585x72.jpg
Posted by Kelly Kozakowski on Oct 28, 2015 2:42 PM CDT
Rita Owens and her daughter Queen Latifah have joined the American Heart Association’s Rise Above Heart Failure movement to spread the word about heart failure and to help others understand the signs and symptoms of the condition, and how to manage it. Rise Above Heart Failure is nationally supported by Novartis Pharmaceuticals Corporation and was created in collaboration with experts across the heart failure community. more...
Posted by Kerstin Wiggins on Oct 22, 2015 11:11 AM CDT
101521_primaryPCI_Banner.jpg

2015 ACC/AHA/SCAI Focused Update on Primary PCI for
Patients with STEMI

Hypertension
  • Based on recently published data, this update revises recommendations for the 2011 PCI guidelines and the 2013 STEMI management guidelines.
  • The focus is on multivessel percutaneous coronary intervention (PCI) and thrombus aspiration in patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI.
  • These timely updates ensure that these guidelines reflect current knowledge, available treatment options, and optimum medical care.

Read the full article in Circulation


Supporting Materials
Posted by Kelly Kozakowski on Oct 21, 2015 3:05 PM CDT
Clinical Science programming aims to provide access to the latest clinical and scientific applications in the diagnosis, medical management, prevention and treatment of cardiovascular disease. Click on the links below to learn more about each Clinical Science track. 

  more...
Posted by Kerstin Wiggins on Oct 19, 2015 1:13 PM CDT
< Prev    1 2 3 4 5 6 7 8 9 ... 47   

Most Recent Comments

Excellent comments , Incidentally , if someone is wanting a DA 31 , my assistant edited a blank document here http://goo.gl/sm5zJK
Looking forward to the new materials and implementing them into our classes.
HI Janet!It looks like the ACLS materials will be available in in Spring 2016. This date could change.http://2015eccguidelines.heart.org/ is a great resource for everything about the new guidelines. One of our distributors, Channing Bete, has an information page about the new guidelines and updated materials that I found very helpful: http://aha...
When can I purchase the 2015 ACLS Manual?
Sorry about that. The correct link is http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/downloadable/ucm_475275.pdf.